Rapamycin inhibits smooth muscle cell proliferation and obstructive arteriopathy attributable to elastin deficiency

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 5, 2013, Pages 1028-1035

  Li, Wei ^a,e   Li, Qingle ^a,e   Qin, Lingfeng ^a   Ali, Rahmat ^a   Qyang, Yibing ^a   Tassabehji, May ^b   Pober, Barbara R ^c   Sessa, William C ^a   Giordano, Frank J ^a   Tellides, George ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

aorta; elastin; mTOR; smooth muscle cell; Williams syndrome

Indexed keywords

BAG 1 PROTEIN; CYCLOHEXIMIDE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; PROCOAGULANT; PROTEASOME;

ARTICLE; CELL DIFFERENTIATION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; SENSITIVITY ANALYSIS; TRANSACTIVATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADULT; ANIMALS; AORTIC STENOSIS, SUPRAVALVULAR; ARTERIAL OCCLUSIVE DISEASES; CELL PROLIFERATION; ELASTIN; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; WILLIAMS SYNDROME;

EID: 84876286272     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300407     Document Type: Article

References (29)

1. Pober BR, Johnson M, Urban Z. Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest. 2008;118:1606-1615.
2. Urbán Z, Riazi S, Seidl TL, Katahira J, Smoot LB, Chitayat D, Boyd CD, Hinek A. Connection between elastin haploinsuffciency and increased cell proliferation in patients with supravalvular aortic stenosis and Williams-Beuren syndrome. Am J Hum Genet. 2002;71:30-44.
3. Williams JC, Barratt-boyes BG, Lowe JB. Supravalvular aortic stenosis. Circulation. 1961;24:1311-1318.
4. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating MT. Elastin is an essential determinant of arterial morphogenesis. Nature. 1998;393:276-280.
5. Li DY, Faury G, Taylor DG, Davis EC, Boyle WA, Mecham RP, Stenzel P, Boak B, Keating MT. Novel arterial pathology in mice and humans hemi-zygous for elastin. J Clin Invest. 1998;102:1783-1787.
6. Faury G, Pezet M, Knutsen RH, Boyle WA, Heximer SP, McLean SE, Minkes RK, Blumer KJ, Kovacs A, Kelly DP, Li DY, Starcher B, Mecham RP. Developmental adaptation of the mouse cardiovascular system to elastin haploinsuffciency. J Clin Invest. 2003;112:1419-1428.
7. Zalzstein E, Moes CA, Musewe NN, Freedom RM. Spectrum of cardiovascular anomalies in Williams-Beuren syndrome. Pediatr Cardiol. 1991;12:219-223.
8. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484.
9. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
10. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained suppression of neointimal proliferation by siro-limus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
11. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694-2700.
12. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
13. Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, Zhao L, Pober JS, Tellides G. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res. 2007;101:560-569.
14. Ge X, Ren Y, Bartulos O, Lee M Y, Yue Z, Kim KY, Li W, Amos PJ, Bozkulak EC, Iyer A, Zheng W, Zhao H, Martin KA, Kotton DN, Tellides G, Park IH, Yue L, Qyang Y. Modeling supravalvular aortic stenosis syndrome using human induced pluripotent stem cells. Circulation. 2012;126:1695-704.
15. Zhang P, Huang A, Ferruzzi J, Mecham RP, Starcher BC, Tellides G, Humphrey JD, Giordano FJ, Niklason LE, Sessa WC. Inhibition of microRNA-29 enhances elastin levels in cells haploinsuffcient for elastin and in bioengineered vessels-brief report. Arterioscler Thromb Vasc Biol. 2012;32:756-759.
16. Hentges KE, Sirry B, Gingeras AC, Sarbassov D, Sonenberg N, Sabatini D, Peterson AS. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc Natl Acad Sci USA. 2001;98:13796-13801.
17. Martinet W, De Meyer GR. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ Res. 2009;104:304-317.
18. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res. 2007;8:15.
19. Campuzano V, Segura-Puimedon M, Terrado V, Sánchez- Rodríguez C, Coustets M, Menacho-Márquez M, Nevado J, Bustelo XR, Francke U, Pérez-Jurado LA. Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome. PLoS Genet. 2012;8:e1002458.
20. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol. 2007;27:1248-1258.
21. Wagenseil JE, Ciliberto CH, Knutsen RH, Levy MA, Kovacs A, Mecham RP. Reduced vessel elasticity alters cardiovascular structure and function in newborn mice. Circ Res. 2009;104:1217-1224.
22. Shifren A, Durmowicz AG, Knutsen RH, Hirano E, Mecham R P. Elastin protein levels are a vital modifer affecting normal lung development and susceptibility to emphysema. Am J Physiol Lung Cell Mol Physiol. 2007;292:L778-L787.
23. Yi T, Cuchara L, Wang Y, Koh KP, Ranjbaran H, Tellides G, Pober JS, Lorber MI. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-gamma. Transplantation. 2006;81:559-566.
24. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the frst 6 months post-renal transplant. Pediatr Transplant. 2005;9:520-522.
25. Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordoñez FA, Santos F. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol. 2007;22:954-961.
26. González D, García CD, Azócar M, Waller S, Alonso A, Ariceta G, Mejía N, Santos F. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol. 2011;26:961-966.
27. Hymes LC, Warshaw BL. Linear growth in pediatric renal transplant recipients receiving sirolimus. Pediatr Transplant. 2011;15:570-572.
28. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490-498.
29. Hirano E, Knutsen RH, Sugitani H, Ciliberto CH, Mecham RP. Functional rescue of elastin insuffciency in mice by the human elastin gene: implications for mouse models of human disease. Circ Res. 2007;101:523-531.